Anti-VHH Antibodies for CART Cell Sorting and Nanobody Purification
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a lack of antibodies with high affinity and specificity for camel-derived nanobodies, hindering the development and optimization of camel-derived nanobodies, particularly in the fields of antibody drug development and immune cell therapy, specifically for identifying, sorting, and magnetic separation of CART cells.
Innovation Solution
Development of antibodies and antigen-binding fragments that specifically bind to VHH domains of camel-derived antibodies, with defined heavy and light chain complementarity determining regions, providing high affinity and specificity, and the ability to recognize conformational epitopes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional scFv technical routes are used for CAR design, then the development process is simpler, but the stability and affinity are poor
Solution Approach 1:
The patent changes the antibody type parameter from conventional scFv to camelid VHH nanobodies, which fundamentally alters the binding characteristics and stability parameters. VHH domains naturally exhibit higher thermal stability and affinity due to their unique camelid origin and structural features, resolving the reliability issue without requiring complex engineering modifications
Solution Approach 2:
The patent utilizes the naturally occurring VHH domain structure from camelid antibodies as a copy of the antigen-binding function, replacing the need for complex scFv assembly. This natural copy provides inherent stability and affinity properties that eliminate the need for additional stabilization engineering
2Productivity
If antibodies for VHH domain identification are not available, then camel-derived nanobody development is hindered, but developing such antibodies increases research capability
Solution Approach 1:
The patent performs preliminary action by developing and providing the anti-VHH domain antibodies in advance, which then serve as ready-to-use reagents for subsequent identification, sorting, and purification processes. This preliminary development eliminates the need for each research group to independently develop their own reagents, thereby improving overall productivity
Solution Approach 2:
The developed anti-VHH domain antibodies serve multiple functions including identification by flow cytometry, sorting of CART cells, and purification of camel-derived nanobodies. This multi-functionality increases research capability across different applications without requiring separate reagent systems for each purpose
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The developed antibodies enhance the identification, sorting, and magnetic separation of CART cells, improving the efficiency and effectiveness of immune cell therapy and antibody drug development.
Implementation Method 1
an antibody or an antigen-binding fragment thereof, which specifically binds to a VHH domain
Data Source
AI summary
The invention provides a group of anti-VHH domain antibodies and use thereof. The present invention further provides use of the described antibodies in the development, screening and purification of nano-antibodies, and use of the described antibodies in the field of immunotherapy.